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Abstract
Background: c-Met is a receptor tyrosine kinase (RTK) that is over-expressed in a variety of cancers and involved in
cell growth, invasion, metastasis and angiogenesis. In this study, we investigated the role of c-Met in
rhabdomyosarcoma (RMS) using its small molecule inhibitor SU11274, which has been hypothesized to be a
potential therapeutic target for RMS.
Methods: The expression level of phosphorylated c-Met in RMS cell lines (RD, CW9019 and RH30) and tumor
tissues was assessed by phospho-RTK array and immunohistochemistry, respectively. The inhibition effects of
SU11274 on RMS cells were studied with regard to intracellular signaling, cell proliferation, cell cycle and cell
migration.
Results: A high level of phosphorylated c-Met was detected in 2 alveolar RMS cell lines (CW9019 and RH30) and
14 out of 24 RMS tissue samples, whereas relatively low levels of phospho-c-Met were observed in the embryonic
RMS cell line (RD). The small molecule SU11274 could significantly reduce the phosphorylation of c-Met, resulting
in inhibition of cell proliferation, G1 phase arrest of cell cycle and blocking of cell migration in CW9019 and RH30
cell lines.
Conclusion: These results might support the role of c-Met in the development and progression of RMS.
Furthermore, the inhibitor of c-Met, SU11274, could be an effective targeting therapy reagent for RMS, especially
alveolar RMS.
Background
Rhabdomyosarcoma (RMS) is the most common soft
tissue tumor in childhood, accounting for up to 50% of
all soft tissue sarcomas [1]. While in adults, RMS repre-
sents about 15-20% of all soft tissue sarcomas [2]. There
are two main histologically distinct subtypes of RMS:
embryonal RMS (ERMS) and alveolar RMS (ARMS) [3].
ERMS is composed of spindle-shaped cells with a stro-
mal rich appearance and occurs mainly in the head and
neck region. It is the most frequently diagnosed variant
with a generally good prognosis and presents early with
an onset around the age of 2-5 years [3,4]. In contrast,
ARMS consists of small, round, densely packed cells
and occurs more often in the trunk and extremities.
ARMS is primarily diagnosed in adolescents and is asso-
ciated with a poor prognosis as patients often present
with metastatic disease [5]. Chemotherapy is the most
common therapeutic option for RMS. The regimens are
typically based on variations of the well-established vin-
cristine, actinomycin D and cyclophosphamide, or a
combination of the alkylating agent ifosfamide with car-
boplatin and the topoisomerase II etoposide [6]. Patients
with metastatic stage IV ERMS and those with ARMS
continue to face a poor prognosis because of diminished
tumor response to current chemotherapeutic options
[5,7]. Therefore, the development of novel therapeutic
strategies for these RMS patients is urgently needed. * Correspondence: dings@unmc.edu
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critical cellular processes such as cell growth, differen-
tiation, neovascularization and tissue repair. In addition
to their importance in normal physiology, aberrant
expression of certain RTKs has been implicated in the
development and progression of many types of cancer.
These RTKs have emerged as promising drug targets for
cancer therapy [8]. RTKs can initiate tumor growth
(Bcr-abl in chronic myelogenous leukemia [9,10]) or
sustain tumor survival (EGFRmut in non-small cell lung
carcinoma [11,12] and c-Kit in gastrointestinal stromal
tumors [13]). Inhibiton of RTKs by small, targeted mole-
cules has exhibited significant clinical benefit in cancer
patients in several selected circumstances.
The present work aims to identify such therapeutic
targets for RMS. Based on the data from phospho-recep-
tor tyrosine kinase (p-RTK) array, a high expression
level of phosphorylated c-Met was observed in 3 RMS
cell lines. c-Met is the receptor of hepatocyte growth
factor/scatter factor (HGF/SF). There is now consider-
able evidence suggesting that aberrant c-Met/HGF/SF
signaling plays a major role in tumorigenesis, invasion,
and metastatic spread of many human tumors, resulting
from mutation or over-expression of the c-Met proto-
oncogene and/or its ligand [14-16].
We hypothesized that c-Met signaling played a key
role in RMS oncogenic signaling and that optimized
therapy targeting c-Met would be effective as a treat-
ment strategy. Recently, a small molecular c-Met inhibi-
tor, SU11274, has been developed and shown to inhibit
c-Met phosphorylation and c-Met-dependent motility,
invasion, and proliferation in lung cancers in vitro
[17,18]. Furthermore, it could abrogate HGF-induced
phosphorylation of c-Met and its downstream signaling
including phospho-AKT, phospho-ERK1/2, phospho-S6
kinase, and phospho-mTOR (mammalian target of rapa-
mycin) [17]. In the current study, we employed and
evaluated the effect of SU11274 on proliferation, cell
cycle and migration of RMS cells.
Methods
Reagents and antibodies
SU11274 was obtained from EMD Biosciences (San
Diego, USA). Hepatocyte growth factor (HGF) was pur-
chased from R&D Systems (Minneapolis, USA). Antibo-
dies against phospho-c-Met (pY1234/1235), total c-Met,
phospho-STAT3 (Tyr705), total STAT3, phospho-AKT
(S473), total AKT, phospho-ERK1/2 (T202/204) and
total ERK1/2 were obtained from Cell Signaling Tech-
nology (Danvers, USA). Myogenin was purchased from
Santa Cruz Biotechnology (Santa Cruz, CA).
Cell lines and cell culture
RMS cell lines (RD and RH30) and the normal muscle
cell line (HASMC) were purchased from American Type
Culture Collection (ATCC). The CW9019 cell line was
kindly provided by Frederic G. Barr (School of Medicine,
University of Pennsylvania). Cells were grown in Dul-
becco’s Modified Eagle Medium (DMEM) (RD, CW9019
and HASMC) and RPMI1640 medium (RH30) (Media-
tech, Manassas, USA) supplemented with 10% fetal
bovine serum (FBS) and 1% penicillin/streptomycin
(Gibco, Carlsbad, USA). The cells were cultured in a
humidified atmosphere at 37°C in 5% CO2.
Patients and tissue samples
A tumor tissue microarray was obtained from US Bio-
max, Inc (Rockville, MD, USA) and consisted of 18
RMS tumor tissues and 3 normal muscle tissues. These
patients included 8 males and 8 females with a median
age of 40 years (range: 18-91). 6 additional ARMS tis-
sues were obtained from Zhongnan Hospital of Wuhan
University (Wuhan, China). There were 3 males and 3
females with a median age of 37 years (range: 13-61).
Written informed consent was obtained from the
patients and the study protocol was approved the Insti-
tutional Review Board (IRB) at the University of
Nebraska Medical Center (UNMC, Omaha, USA).
Phospho-RTK array
A human p-RTK array kit (R&D Systems, Minneapolis,
USA), which has a greater sensitivity than immunopreci-
pitation analysis, was used to simultaneously detect the
relative tyrosine phosphorylation levels of 42 different
RTKs in RMS cell lysates. Each array contained duplicate
validated control and capture antibodies for specific
RTKs. RMS cells were cultured for 24 h in serum-free
medium at 37°C in a humidified atmosphere of 5% CO2
in air, and then immediately placed on ice, washed twice
with chilled PBS, and isolated using chilled lysis buffer
(20 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1% NP-40, 2.5
mM EDTA, 1 mM sodium orthovanadate, 10% glycerol,
10 μg/ml aprotinin, 10 μg/ml leupeptin). Total protein
concentration was quantitated using a Coomassie Brilli-
ant Blue (CBB) assay kit (Pierce, Rockford, USA). RTK
array analysis was performed according to the manufac-
turer’s protocol. In brief, the array membrane was
blocked and incubated with cell lysates for 2 h, then trea-
ted with HRP conjugated anti-phospho-tyrosine antibody
for 2 h at room temperature. The membrane was devel-
oped with ECL detection reagent (Pierce, Rockford,
USA), and RTK spots were visualized using Kodak XAR
film (Fisher Scientific, Houston, USA).
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The tissue slides were treated with xylene to remove
paraffin, then with a decreasing gradient of ethanol.
Then the slides were pre-treated in 0.01 M citrate buffer
(pH 6.0) and heated in a microwave oven (98°C) for 10
min. Endogenous peroxidase was blocked for 20 minutes
with a 3% hydrogen peroxide solution. The slides were
processed for detection of phospho-c-Met expression
using the primary antibody for phospho-c-Met
(Tyr1234/1235, 1:160 dilution) and a secondary antibody
( H R P - c o n j u g a t e dg o a ta n t i - r a b b i tI g G )i n1 0 %g o a t
serum. The reaction products were visualized with dia-
minobenzidine (DAKO, Denmark). For the tissue array,
normal muscle tissues were included as negative con-
trols and duplicate specimens were included in the
array. For tissue slides, the primary antibody was
replaced with IgG for a negative control. All slides were
independently analyzed by two investigators. The stain-
ing score was calculated from the staining intensity and
percentage of positive staining cells. The staining inten-
sity was scored as 1 (very weak), 2 (weak), 3 (moderate)
and 4 (intense). The positive rate score was 0 (0-10%), 1
(10-30%), 2 (30-50%), 3 (50-75%) and 4 (> 75%). The
score of each slide was the sum of intensity and positive
rate scores. The staining results were categorized as low
expression (the score ≤ 3) and high expression (the
score > 3).
Proliferation/cell survival assay
RMS cells were plated at 1 × 10
4 cells/well in 96-well
plates and allowed to adhere overnight. Serum-starva-
tion was performed for 6 h. Then the cells were treated
with SU11274 at the indicated concentrations for 72 h
with or without the presence of HGF (10 ng/ml).
Dimethyl sulfoxide (DMSO) was added to the control
with the same volume. The viability of the cells was
determined by the MTT proliferation/viability assay
(Invitrogen, Carlsbad, USA) according to the manufac-
turer’s instruction.
Western blot
Western blot analyses were performed to detect specific
phosphorylation of c-Met and other signaling molecules
via HGF and inhibition of phosphorylation with
SU11274. RMS cells were deprived of growth factors by
incubating them in serum-free medium for 6 h followed
by treatment with SU11274 (5 μM) or DMSO for 24 h.
Then the cells were either left untreated or they were
treated with HGF (10 ng/ml) for 7.5 min. For the lysate
preparation, cells were first washed with PBS and lysed
in 2× sodium dodecyl sulphate sample buffer (100 mM
Tris-HCl pH6.8, 200 mM DTT, 4% SDS, 20% glycerol
and 0.2% bromophenol blue). Then the cell lysates were
separated on 8% or 10% SDS-PAGE. Proteins were
transferred to an immobilization membrane (Millipore,
Billerica, USA) and immunoblotted using enhanced che-
miluminescence (ECL; GE Healthcare Life Sciences, Pis-
cataway, USA).
Cell cycle analysis
RMS cells were treated with SU11274 (5 μM) or an
equal volume of DMSO for 24 h. Cells were collected
and stained with propidium iodide according to the
standard protocol of the FACS core facility (UNMC,
Omaha, USA). The cell cycle was analyzed by a BD
FACSCalibur flow cytometer (BD Biosciences, San Jose,
USA) with CellQuest Pro software (BD Biosciences,
USA).
Wound healing assay
RMS cells were seeded at a density of 5 × 10
5 cells per
well in a 6-well plate and grown overnight to confluence
in complete medium. The cells were serum starved for 6
h and then treated with DMSO or SU11274 (5 μM) for
24 h, respectively. The monolayer was scratched with a
pipette tip and washed with phosphate buffered saline
(PBS) to remove floating cells. The scrape was moni-
tored and photographed after 24 h incubation.
Trans-well assay
Trans-well motility assays were performed utilizing 8
μm pore, 6.5 mm polycarbonate trans-well filters
(Costar, Cambridge, USA) according to the standard
protocol. In brief, RMS cells were plated onto the upper
well of the trans-well previously coated with 50 μlo f
Matrigel Basement Membrane Matrix (BD, Franklin
Lakes, USA) and then treated with DMEM or SU11274
(5 μM) for 24 h. The noninvasive cells on the upper sur-
face of the membrane were removed with a cotton swab.
Cells that attached to the lower surface of the mem-
brane and migrated through the Matrigel matrix were
fixed with glutaraldehyde, stained with cresyl violet,
solubilized in 10% acetic acid solution, and quantified by
spectrophotometric analysis (570 nm).
Results
Expression of phosphorylated RTKs in RMS
To evaluate the expression of phosphorylated RTKs in
RMS, the phospho-RTK array was used with three RMS
cell lines RD (ERMS), CW9019 (ARMS), RH30 (ARMS)
and one normal muscle cell line HASMC (Figure 1A-D).
Thirteen RTKs were detected in the RMS cell lines,
including HGFR (c-Met), epidermal growth factor recep-
tor (EGFR), insulin growth factor-I receptor (IGF-IR),
ErbB2, ErbB3, c-Ret, MSPR, VEGFR, Mer, EphA7,
FGFR, EphB2 and TrkA. The expression levels of RTKs
for each cell line are shown in Figure 1E. The phosphor-
ylation level of c-Met was significantly higher in ARMS
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ERMS cell line (RD) in comparison with the normal
muscle cell line HASMC.
Expression of phosphorylated c-Met in tissue samples
To evaluate the possible clinical significance in RMS, the
expression of phosphorylated c-Met was assessed in 24
RMS tissues and 3 normal muscle tissues using immu-
nohistochemistry. Phosphorylated c-Met protein was
localized in both the membrane and the cytoplasm (Fig-
ure 2). The results showed that phospho-c-Met was
over-expressed in 14 of 24 (58.3%) RMS tissues, includ-
ing 5 ERMS, 7 ARMS and 2 Pleiomorphic RMS (Table
1). None of the normal muscle tissues stained positively.
Effect of SU11274 on the proliferation and c-Met
signaling pathway
To determine whether c-Met was a potential therapeutic
target, the high specific c-Met inhibitor SU11274 was
used to block c-Met function in 3 RMS cell lines and 1
normal muscle cell line, HASMC. In CW9019 and
RH30 cell lines, which expressed high levels of phos-
pho-c-Met, the IC50 of SU11274 was 2.5 μM; whereas in
the RD cell line, which expressed a lower level of phos-
pho-c-Met, the IC50 was over 7.5 μM. The effect of
SU11274 on the normal muscle cell line, HASMC, was
mild as shown in Figure 3A. The results indicated that
the cytotoxicity of SU11274 might be correlated with
the expression level of phosphorylated c-Met. When the
cells were treated with SU11274 in the presence of HGF
(10 ng/ml) (Figure 3B), more cells survived than when
HGF was omitted (Figure 3A). The results suggested
that HGF could protect cells from the cytotoxicity of
SU11274, which might be due to an increased phos-
phorylation level of c-Met caused by HGF.
We tested the effects of SU11274 and HGF on the
phosphorylation level of c-Met in RMS cell lines. The
results showed that treatment with HGF increased the
autophosphorylation of c-Met at the activation loop site
phospho-epitope (pY1234/1235). Whereas, SU11274 sig-
nificantly reduced phosphorylation of the above tyrosine
residues at the activation site (Figure 3C).
Figure 1 Expression of phosphorylated RTKs in RMS cell lines. Multiple RTKs are detected in RMS cell lines RD (A), RW9019 (B), RH30 (C) and
normal muscle cell line HASMC (D). Whole-cell extracts were incubated on RTK antibody arrays and phosphorylation status was determined by
subsequent incubation with anti-phosphotyrosine horseradish peroxidase. Each RTK is spotted in duplicate and the pairs of dots in each corner
are positive controls. Each pair of positive RTK dots is denoted by a red numeral, with the identity of the corresponding RTKs listed below the
arrays. E, thirteen overexpressed RTKs were semi-quantified with Image J software (NIH, USA).
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that have been shown to be important for the activation
of pathways involved in cell proliferation, differentiation,
survival, motility and death, especially the phosphoinosi-
tide-3-kinase (PI3K) pathway and the mitogen activated
protein kinase (MAPK) pathway. We then analyzed the
phosphorylation level of c-Met, and its downstream sig-
naling molecules AKT, STAT3 and ERK1/2 with or
without SU11274 treatment (Figure 3D). We observed
that the phosphorylation of c-Met, AKT and ERK1/2
was abolished by SU11274 in both HGF-induced and
non-induced conditions in CW9019 and RH30 cell
lines, whereas the effect of SU11274 was weak in the
RD cell line. This could be correlated with the expres-
sion level of phosphorylated c-Met. However, the phos-
phorylation level of STAT3 was not influenced by
SU11274 in any of the three cell lines. The results indi-
cated that phosphorylation of c-Met could activate the
PI3K and MAPK signaling pathways but not the STAT
pathway.
Effect of SU11274 on cell cycle and apoptosis in RMS cell
lines
The effect of SU11274 on the cell cycle and apoptosis
was evaluated by flow cytometry. Cells were treated with
DMSO or SU11274 (5 μM) and the different phases of
cell cycle distribution were determined. The percentage
of cells in G1 phase increased significantly whereas the
percentage of cells in S phase and G2/M phase
decreased (Table 2). In addition, there was also an
increase in apoptosis after SU11274 treatment. These
data indicated that SU11274 could induce G1 cell cycle
arrest and apoptosis, and both events in combination
might contribute to the reduced cell growth of SU11274
treated RMS cells.
SU11274 inhibited cell motility in RMS cell lines
Cell motility was evaluated using the in vitro wound heal-
ing/scratch assay (Figure 4A) and the trans-well assay
(Figure 4B and 4C). The results from the scratch assay
showed that the motility of CW9019 and RH30 cell lines
was inhibited by SU11274, while the RD cell line motility
was not inhibited. The RD cell line grew nearly to conflu-
ence like the SU11274 untreated controls. This might be
because the effectiveness of SU11274 depends on the
phosphorylation level of c-Met. However, inhibition of
cellular proliferation may also contribute to the effects
seen in the scratch assay. We also performed trans-well
assays to quantify the effect of SU11274 on cell motility.
Figure 2 Analysis of the expression and localization of phosphorylated c-MET in RMS tissue samples. Represent images of HE staining
and IHC staining of myogenin and phospho-c-Met were shown. Case 1 is phospho-c-Met negative whereas case 2 is phospho-c-Met positive.
Positive staining of phospho-c-Met was observed in both membrane and cytoplasm. Magnification, ×100 and ×400 (inserts).
Table 1 Summary of phosphorylated c-Met expression in
RMS tissue samples (n = 24)
Histology type Low expression (n/%) High expression (n/%)
ERMS 8/33.3% 5/20.9%
ARMS 1/4.2% 7/29.2%
Pleomorphic RMS 1/4.2% 2/8.3%
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migration of CW9019 and RH30 cells, while there was
little inhibition in RD migration. In addition, studies
were performed in the presence of HGF which served as
the ligand for c-Met. The results showed that HGF treat-
ment reduced SU11274 inhibition in CW9019 and RH30
cells but had little effect in RD cells, which was consistent
with the observations in the cell survival assay.
Discussion
The successful development of molecular agents that will
inhibit tumor growth is dependent on the identification of
Figure 3 Inhibition effect of SU11274 on proliferation and intracellular signaling in RMS cells. A and B, Cells were plated in 96-well plates
and allowed to adhere overnight followed by treatment with the indicated concentrations of SU11274 without (A) or with (B) 10 ng/ml HGF.
MTT proliferation/viability assay was performed after 72 h treatment. Data represent mean ± SD for triplicate independent experiments. C and D,
expression of c-Met (C) and its downstream kinases (D) modulated in three RMS cell lines after treatment with 5 μM SU11274 for 24 h. RMS cells
were pre-starved and stimulated with 10 ng/ml of HGF for 7.5 min. Cells were harvested and immunoblotted using phospho-specific antibodies
against phospho-c-Met (pY1234/1235), phospho-STAT3 (Tyr705), phospho-AKT (S473) and phospho-ERK1/2 (T202/204). *short exposure; **long
exposure.
Table 2 The percentage of cells in different cell cycle phases
% of cells in phase RD CW9019 RH30
Control SU11274 SD Control SU11274 SD Control SU11274 SD
G1 51.35 59.40 0.5 50.48 66.16 0.7 53.57 68.40 0.8
S 22.65 25.40 0.2 23.16 21.15 0.3 27.87 19.04 0.2
G2/M 25.99 15.20 0.1 26.36 12.68 0.3 18.56 12.56 0.1
Apoptosis 0.16 2.84 0.02 0.10 5.12 0.07 0.16 4.61 0.03
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density of 5 × 10
5 cells per well in a 6-well plate and grown overnight to confluence in serum containing media. The cells were serum starved
for 6 h and pretreated with DMSO or SU11274 (5 μM), respectively. The monolayer was scratched with a pipette tip and washed with 1 × PBS to
remove floating cells. The scrape was monitored and photographed after 24 h. B and C, SU11274 inhibited trans-well migration with (B) or
without (C) presence of HGF. Data represent mean ± SD for triplicate independent experiments. * P < 0.05.
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development. Receptor tyrosine kinases (RTKs) are key
regulators of critical cellular processes which are activated
through phosphorylation or over-expression in the devel-
opment and progression of many types of cancer. They
have emerged as promising drug targets for cancer
therapy.
In the current study, we identified thirteen phosphory-
lated RTKs that were over-expressed in three RMS cell
lines RD (ERMS), RW9019 (ARMS) and RH30 (ARMS)
using the phospho-RTK array (Figure 1). Importantly,
other groups have also reported the over-expression of
several RTKs in these cell lines. For instance, it has
been reported that IGF-IR is highly expressed in RD
and RH30 cell lines and could be a potential therapeutic
target for RMS both in vitro and in vivo [19]. In addi-
tion, EGFR is highly expressed in ERMS tumor tissue
[20-22]. Expression of ErbB2 is more prevalent in
ARMS tumor tissue where it is found in the majority of
RMS tumors of the head and neck [23]. ErbB3 is over-
expressed in RMS cells and may play a role in regulating
differentiation [24].
We have focused on another RTK, HGFR/c-Met,
mainly due to its over-expression in all three RMS cell
lines, which was consistent with previous reports
[25,26]. We found that 14 of 24 (58.3%) RMS tumor tis-
sues showed high expression level of phosphorylated c-
Met (Figure 2). Over-expression of HGF and c-Met has
been reported to correlate with increased aggressiveness
of tumors and a poor prognosis in cancer patients [27].
In tumor cells, c-Met activation triggers a diverse series
of signaling cascades resulting in cell growth, prolifera-
tion, invasion, and protection from apoptosis [28,29].
Data from cellular and animal tumor models suggest
that the underlying biological mechanisms for tumor-
genicity of c-Met are achieved in three different ways:
(i) with the establishment of HGF/c-Met autocrine
loops; (ii) via c-Met or HGF over-expression; and (iii) in
the presence of kinase-activating mutations in the c-Met
receptor coding sequence [28,30-32]. There were no
activating mutations in the tyrosine kinase region of the
c-Met receptor in the RMS cell lines used in our experi-
ments (RD, CW9019 and RH30), and no functional
autocrine regulatory loops were present. One explana-
tion for higher expression of c-Met in these RMS cells
is modulation by the PAX3/7-FOXO1 fusion gene [33].
In this study, both ARMS cells lines have the PAX3-
FOXO1 (RH30) and PAX7-FOXO1 (CW9019) translo-
c a t i o n sa n de x p r e s sm o r ep hosphorylated c-Met than
the PAX-FOXO1-negative ERMS cell lines (RD).
It has been proposed that targeting c-Met by novel
biological agents will inhibit tumor progression at the
molecular level. Recently, cell proliferation in vitro and
tumor burden in mouse xenograft models were
decreased by targeted knockdown of c-Met using siRNA
in human RMS cell lines [34,35]. In order to improve
clinical application of this concept, several different stra-
tegies are being explored, including the development of
competitors of c-Met/HGF, monoclonal antibodies
directed against HGF and c-Met, and small-molecule
tyrosine kinase inhibitors directed against c-Met [8].
We hypothesized that inhibition of phosphorylation
on c-Met with the specific, small-molecular inhibitor
SU11274 might induce anti-tumor effects. We examined
the cytotoxicity of SU11274 without and with HGF
treatment on three RMS cell lines and one normal mus-
cle cell line (Figure 3A and 3B). SU11274 inhibited the
proliferation of RMS cells that exhibited high levels of
phosphorylated c-Met in a dose dependent manner.
This suggested that the inhibitory effects mgithe be
associated with c-Met driven proliferation of RMS cell
lines. In addition, the phosphorylation levels of AKT
and ERK 1/2 downstream in the c-Met signaling path-
ways were almost completely abolished when phos-
phorylated c-Met was blocked by SU11274 in RMS cell
lines (Figure 3C and 3D), agreeing with the results from
previous studies in several types of malignancies
[17,36,37]. The results indicated that the advantage of c-
Met inhibition was that multiple pathways were silenced
by a single upstream intervention.
RMS cells, especially ARMS, show strong directional
chemotaxis [33]. Accordingly, we performed wound heal-
ing and trans-well assays to evaluate the effect of SU11274
on RMS cell migration. Both of the results showed that
the migration of CW9019 and RH30 cells was significantly
inhibited by SU11274 compared with RD cells, which indi-
cated that the ability of SU11274 to block cellular migra-
tion might correlate with the expression level of phospho-
c-Met (Figure 4). There are several RD derived clones
which express quite high levels of phospho-c-Met. There-
fore, the effects of SU11274 treatment on these RD clones
may be as significant as we observed in CW9019 and
RH30 cells. In addition, we found that SU11274 treatment
induced G1 phase arrest and apoptosis in RMS cells
(Table 2), which was also observed in other tumors such
as NSCLC [17], melanoma [36] and head and neck squa-
mous cell carcinoma [37].
Conclusions
We have shown that phosphorylated c-Met was over-
expressed and activated as a functionally important
receptor in RMS (especially ARMS) cell lines and tumor
tissues. To our knowledge, the present study is the first
to verify the antitumor effects of c-Met inhibitor
SU11274 in RMS cells. However, additional in vivo stu-
dies are needed to determine whether inhibiting the
phosphorylation of c-Met by SU11274 is a viable thera-
peutic agent for RMS.
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